Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
SALT LAKE CITY, May 30, 2017 -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Goldman Sachs Global Healthcare Conference at 10:00 a.m. PDT on June 13, 2017, at the Terranea Resort in Rancho Palos Verdes, California.
The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’s website at www.myriad.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
Media Contact: Ron Rogers (801) 584-3065 [email protected] Investor Contact: Scott Gleason (801) 584-1143 [email protected]
